IRulya Therapeutics
IRLA· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +79.1% in FY2025
Dirk Thye is the CEO of IRulya Therapeutics and was paid $2.5M in FY2025 (Dec), down 9%.
Pay$100 in the stock at the end of FY21 → $27
Executives3
See all- 1Dirk ThyeChief Executive Officer and Chief Medical OfficerFY2025
- 2Brendan HannahChief Operating Officer, Chief Business Officer and Chief Compliance OfficerFY2025
- 3Charles RyanPresidentFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allIRulya Therapeutics paid its 3 named executives $4.9M in total in FY2025 (Dec). CEO Dirk Thye was paid $2.5M of that.
| Name | |||
|---|---|---|---|
| Dirk ThyeChief Executive Officer and Chief Medical Officer | |||
| Brendan HannahChief Operating Officer, Chief Business Officer and Chief Compliance Officer | |||
| Charles RyanPresident |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for IRulya Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board3
See all- David A. LamondChair · 10 yr on the boardIndependentCompensation (Chair), Nominating and Corporate Governance (Chair)—Paid as an executive
- Christopher J. SennerDirector · 6 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive
- Dirk ThyeDirector · 3 yr on the boardNot independent—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 27, 2026 | FY2025 |
| Annual report | 10-K | Apr 10, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 23, 2025 | FY2024 |
| Annual report | 10-K | Mar 24, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 24, 2024 | FY2023 |
| Annual report | 10-K | Apr 1, 2024 | FY2023 |
